A unique mission
Medunik USA is dedicated to providing Americans suffering from rare diseases with access to orphan drugs that are not currently available in the U.S. We make these treatment options available by building strategic partnerships with international companies to bring their products to the American market.
Through in-licensing partnerships, Medunik USA offers turn-key operations and provides medical scientific liaisons, approval and market access processes and marketing for orphan disease treatments.
Medunik USA is part of North American Boivin Family Pharmaceutical Group (Groupe Pharmaceutique Boivin), founded in 1955 by Louis Boivin.
In 2009, the company launched Medunik Canada to bring orphan drugs to Canadians with rare diseases.
Today, Medunik USA brings orphan drugs to the U.S. market to provide Americans with rare diseases with the life-changing and potentially life-saving treatment options they deserve.
Resources and Competencies
Medunik USA has the financial, human and scientific resources necessary to fulfil its mission of making orphan drugs available in the U.S. for Americans with rare diseases.
- Solid and independent financial backing
- Extensive network of relationships and partnerships
- Knowledge, skills and experience
- Success in speciality markets
- Proven partnering abilities
- Unique educational programs
- History of pioneering and innovation
- Dedicated to scientific excellence and discovery
Message from our management
"Patients in the U.S. living with rare diseases don’t always have access to the orphan therapies available in other countries. When a disease is so rare, developing and marketing a medication to treat it can simply be too long and expensive a process for most drug companies to undertake. But Medunik USA believes that patients suffering from rare diseases are no less deserving of effective treatment options than those suffering from more common conditions. That’s why Medunik USA has made it our mission to bring orphan drugs to the U.S. We form strategic partnerships with pharmaceutical and biopharmaceutical companies worldwide that enable us to bring orphan drugs to the U.S. market and ensure that Americans living with rare diseases have access to the most effective treatments available anywhere."
- Dean Hopkins, General Manager, Medunik USA
Compliance with all laws, regulations, company policies and other best practices applicable to the organization by all Medunik USA employees is critical to Medunik USA’s professional standards and corporate success. Medunik USA’s Compliance Program incorporates the fundamental elements addressed within the Office of the Inspector General’s (OIG) “Compliance Program Guidance for Pharmaceutical Manufacturers”.